-
1 Comment
Sinopharm Group Co., Ltd is currently in a long term uptrend where the price is trading 7.8% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.1.
Sinopharm Group Co., Ltd's total revenue rose by 13.0% to $253B since the same quarter in the previous year.
Its net income has increased by 30.9% to $4B since the same quarter in the previous year.
Finally, its free cash flow grew by 13.5% to $36B since the same quarter in the previous year.
Based on the above factors, Sinopharm Group Co., Ltd gets an overall score of 5/5.
| ISIN | CNE100000FN7 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Medical Distribution |
| Target Price | 22.6121 |
|---|---|
| Dividend Yield | 4.1% |
| Market Cap | 55B |
| PE Ratio | 7.55 |
| Beta | 0.63 |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1099.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
